Drugs / MBS-COV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05677893 | Nov 2022 → Mar 2023 | COVID-19 | Oneness Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05941793 | Sep 2023 → Aug 2024 | — | Oneness Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBS-COV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05677893 ↗ |
| Route | Inhaled | “MBS-COV for inhalation” NCT05941793 ↗ |